Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
about
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discoveryFragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activitiesDrug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.Polymorphisms in NAT2 (N-acetyltransferase 2) gene in patients with systemic lupus erythematosus.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Acetylator phenotypes in Papua New Guinea.Gene environment interactionObservation and experiment on the cusp of collaboration: a parallel examination of clinical pharmacology and pharmacoepidemiology.The relationship between genetics and environment in the pathogenesis of rheumatic diseasesPharmacogenomics: a systems approach.Betaxolol and drug-induced lupus complicated by pericarditis and large pericardial effusion.Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatinBioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsIsoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro.Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro.A review and assessment of potential sources of ethnic differences in drug responsiveness.Drug-induced glomerular disease: immune-mediated injury.Adverse drug effect-reactive metabolites and idiosyncratic drug reactions: Part I.Polymorphically acetylated aminoglutethimide in humans.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies.Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytesThe role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.Pharmacogenetics of antiarrhythmic therapy.Pharmacogenomics: challenges and opportunitiesMetabolomics reveals the metabolic map of procainamide in humans and mice.Drug therapy considerations in arrhythmias in childrenDeleterious effects of reactive metabolites.Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.Drug-induced nephropathies.Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.Antiarrhythmic therapy: clinical pharmacology update.Genetic differences in drug disposition.Procainamide-induced lupus in the elderly.Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
P2860
Q26995125-27FE203D-B8EC-4267-B03B-1A5F8809E6B8Q31132161-B6CB8317-8093-4D9F-96AE-7490895B9E3BQ33396340-9F5DF825-1D50-46E9-AAC2-A3DD720299D1Q33436120-6B14E59A-BD79-41E3-A18B-26DADCBCFE97Q33538523-376FB130-FF27-40B7-B810-EA720735C26FQ33670130-DF6E634D-9061-43BA-BD31-11466428088DQ33703714-D6D8F052-5202-4323-AD7B-EC003B1B8BA3Q34024124-9E7378C4-ACE3-4E76-8F62-F88B1BD5FA4BQ34107585-DFB62F23-FBF3-4614-874A-A598DF70C9F9Q34137575-484F26F7-7346-4ADD-9144-E6CF2271A05FQ34186520-0BF95645-3A39-4750-A614-BB51EF9E825EQ34194662-E7DA5113-5CA0-477B-843C-82B11D5737ACQ34397894-53CB7DAF-A4DA-4299-B8EA-81BBE47245ADQ34403403-69727BF5-F2EC-43A8-AA8A-6046E337D7B2Q34450224-5C99C76A-CED9-4DBB-A5B2-87089A758B68Q34571027-7709A190-D3A5-4B23-8C44-BA1ECE1D54B0Q35202118-F6F9A69D-5E73-40FD-B2AB-811C8D71BC76Q35217493-ACCDA20F-A49F-4409-9E63-03606F2A77E8Q35816996-331643EC-4E57-4C20-800C-4C3F08444834Q35953632-53A4A58F-973D-4177-80AD-18EF4FD5A72AQ36046979-C5E030E1-721E-407E-92D8-697AD5F7CB55Q36061821-D9811B60-225C-4561-A339-5BBDC9C236CCQ36084984-9E0E8188-6F2B-4F1E-831F-E2F028946BD6Q36283262-1207E793-C3F7-4109-BAFE-25CA53572135Q36312078-7133693E-3489-4301-B5B4-0EAE393297DDQ36548713-6BD1DAF2-70C0-4DE7-AFC5-675BE5F0059DQ36658763-72058142-F331-4880-AD75-9CD3535C1BA9Q36880244-21AA05D3-66A7-44E1-AE16-A53787B7D7E5Q37235054-F8AC4155-6B67-4BCF-94EF-BFE13929ED2EQ37802740-9166C92D-9E59-42ED-9A70-325DDB6AEC12Q38177342-1CED0EB7-8B54-4A19-ACD6-99DC853175B3Q38944104-9F077D3C-557E-40FF-8CC0-CE093985F2D6Q39037643-03AE0368-66A7-4859-A635-ECCC569E0F67Q39595774-3E999B14-8B13-4463-B391-C6C83250DC17Q40187593-55D866EB-C8FA-439E-AB08-5E2431AEA217Q40645305-924E05EA-CF05-4F69-905A-CAC65F690633Q40915820-0A573747-54A7-43B8-9CCC-CBCE8BE3954BQ41690934-E3F7C34D-8F9D-49E1-B47D-A8276BF72568Q42284991-A649676D-F4BB-41CD-A66E-85311E8B1EBBQ42643146-627FEEA4-8CE0-4169-BA9C-4F74FAF71B6A
P2860
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Effect of acetylator phenotype ...... bodies and the lupus syndrome.
@en
type
label
Effect of acetylator phenotype ...... bodies and the lupus syndrome.
@en
prefLabel
Effect of acetylator phenotype ...... bodies and the lupus syndrome.
@en
P2093
P1476
Effect of acetylator phenotype ...... bodies and the lupus syndrome.
@en
P2093
P304
P356
10.1056/NEJM197805252982101
P407
P577
1978-05-01T00:00:00Z